Table 1.
Key data from the CLASSIC and LOVIT trials
| CLASSIC4 | LOVIT5 | |
|---|---|---|
| Sites | Europe | Canada, France, New Zealand |
| Design | Open-label RCT | Blinded RCT |
| No. of patients | 1,554 | 863 |
| Intervention | Restrictive fluid regimen | IV ascorbic acid (200 mg/kg per day for 96 h) |
| Control | Standard fluid regimen | Placebo |
| Primary outcome | 90 day mortality: adjusted RR 1.00 (95% CI 0.89–1.13) | Death or persistent organ dysfunction: adjusted RR 1.15 (95% CI 0.90–1.47) |
| Primary outcome: AKI subgroup analysis | Absolute % point difference –0.8 (–8.0 to 6.7) | Not available |
| Secondary outcome: incidence of stage III AKI | Risk ratio 0.94 (95% CI 0.79–1.13) | Risk ratio 1.00 (95% CI 0.85–1.19) |
RCT, randomized controlled trial; RR, relative risk.